The authors claim that an ideal drug regimen for ALS is one including glutamate antagonists, antioxidants, a centrally acting anti-inflammatory agent, microglial cell modulators (TNF-α inhibitors), an antiapoptotic agent, 1 or more neurotrophic growth factors, and a mitochondrial function-enhancing agent. Preclinical data indicates that cannabis appears to have activity in all of those areas (antioxidative, anti-inflammatory, and neuroprotective effects).
In the G93A-SOD1 ALS mouse, cannabis has translated to prolonged neuronal cell survival, delayed onset, and slower disease progression. Cannabis also has properties applicable to symptom management of ALS, including analgesia, muscle relaxation, bronchodilation, saliva reduction, appetite stimulation, and sleep induction. Hence the authors argue for clinical trials with cannabis with the potential objectives of slowing ALS progression, extending life expectancy and substantially reducing the overall burden of the disease.